Federal marijuana rescheduling would represent a historic policy change with major implications for cannabis research and industry—but it should be viewed as a “transitional” step that must be followed up with comprehensive reform to better align state and federal law while promoting equity, a new academic paper argues.
Professors at the University of California published the analysis in the journal Cannabis & Cannabinoid Research, focusing on the impacts and limitations of moving marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA) as federal agencies recommended following a scientific review.
To be sure, rescheduling “would be the most significant federal cannabis policy shift in more than five decades, yet its legal and practical consequences are widely misunderstood,” the paper says, noting that the move has the potential to “expand research capacity and strengthen incentives for [Food and Drug Administration, or FDA] compliant development.”
But the reform would not federally legalize marijuana or legitimize state cannabis markets, and confusion around the continued legal disconnect could prove problematic as the reform movement continues to expand, it points out.
The authors also emphasized that “rescheduling does not expunge records, repair past harms, or ensure equitable participation and may accelerate consolidation
Read full article on Marijuana Moment
